The common treatment of wet AMD targets the overexpressed vascular endothelial growth factor A (VEGFA), implicated in CNV formation, by means of the intravitreal injection of anti-VEGF antibodies [6,11,12,13,14]. Here, VEGFA is linked to wet macular degeneration.